IXENSOR
27.7.2021 08:32:07 CEST | Business Wire | Press release
iXensor Co., Ltd. (6734.TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005852/en/
iXensor launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal . The PixoHealth Pass Admin App is a virtual gatekeeper, which screens and verifies the COVID-19 related health conditions through a scan of QR code displayed by PixoHealth Pass App users. In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest® POCT Analyzer simultaneously.
With PixoHealth Pass apps and in-app consent, the authorized institution can track app users’ rapid test results, vaccination status and COVID-19 related symptoms directly on the web portal. The utilization of PixoHealth Pass Admin Web Portal, PixoTest POCT Analyzer and PixoHealth Pass App fully digitizes the data management processes with a one-time setup. In addition, PixoHealth Pass Admin App allows organizations to configure health-data based access management rules for keeping SARS-CoV-2 from causing cluster infections.
The cloud-based data management solution helps streamline COVID-19 testing and point-of-entry screening for semi-closed communities, such as schools, corporations, healthcare facilities, and public health organizations. More important, the computer-vision enabled PixoTest POCT Analyzer detects COVID-19 antigens more accurately than most COVID-19 self-tests. In addition, its wireless connectivity enables easy, fast reporting and case management for routine testing and mass screening, making the reopen of social and economic activities safer and more sustainable.
The PixoTest® POCT COVID-19 Antigen Test detects the nucleoproteins of SARS-CoV-2 in the human nasopharynx and anterior nasal cavity. According to recent technical validation, the PixoTest® POCT COVID-19 Antigen Test proved its ability to capture recombinant nucleocapsid proteins of notable variants, including Alpha, Beta, Gamma and Delta. These variants have undergone mutations in spike proteins on the virus’s surface, which are known to cause the reoccurrences of outbreaks internationally. Thus, seven months post the first launch of COVID-19 vaccines, the evolution of coronavirus seems to have stayed ahead of vaccinations.
iXensor Chairmen Dr. Peter Fitzgerald commented, “The COVID-19 rapid antigen test with an integrated data management solution provides the exact security mechanism demanded to protect homes, schools, businesses and communities from being affected by new outbreaks.
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, and cardiovascular diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convatec Survey Challenges Assumptions About Leakage in Ostomy Care6.10.2026 09:00:00 CEST | Press release
New global findings highlight the role of peristomal skin health in improving outcomes and confidence for people living with an ostomy Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, today released Rethinking leakage in ostomy care, new international research highlighting a significant gap in how peristomal skin health is understood and managed in ostomy care. The findings indicate that skin health plays a critical role in preventing leakage, and supporting confidence in daily life, yet remains widely under-recognised in routine care. For many people, leakage is not only a clinical or product issue; it can shape whether they feel able to travel, exercise, socialise or take part fully in everyday life. More than half of respondents said they avoid such activities due to worry about their ostomy. The results of the survey, which included more than 1,800 people living with an ostomy and over 400 healthcare profes
Oulu2026 Boosts Tourism as Björk, Art and Technology Lead the European Capital of Culture Year’s Finale6.10.2026 09:00:00 CEST | Press release
The Oulu2026 European Capital of Culture programme has attracted visitors to northern Finland and contributed to strong tourism growth. According to Visit Oulu statistics, Oulu recorded nearly 475,000 registered overnight stays between January and August 2026, an increase of 12 per cent year on year. International overnight stays rose by 21 per cent to more than 96,600, while domestic overnight stays increased by 9 per cent. The trend continued in August, when international overnight stays grew by almost 29 per cent year on year. Hundreds of events combining art, technology, science, music, theatre and sport continue throughout the final months of 2026. “The programme’s diversity is clearest in the final months. There is something for culture enthusiasts and families alike, with experiences that cannot be found anywhere else. If ever there was a time to visit Oulu, it is now,” says Samu Forsblom, Programme Director of Oulu2026. A major highlight is the Lumo Art & Tech Festival, taking
Ant International and HSBC Expand Real-Time Treasury Management Services to the Middle East6.10.2026 08:30:00 CEST | Press release
Collaboration extends Ant International’s use of tokenised deposits in UAE, supporting faster treasury transactions Ant International today announced an expanded collaboration with HSBC to enhance real-time treasury management services in the Middle East. By leveraging HSBC’s global Tokenised Deposit Service (TDS), Ant International aims to improve the efficiency of its treasury operations across the region. As part of the collaboration, Ant International has successfully completed pilot transactions across two payment corridors connecting the United Arab Emirates and Hong Kong: Intra-UAE dirham transfers: Real-time, dirham-denominated tokenised deposit transactions within the UAE. Cross-border US dollar payments initiated from the UAE: US dollar-denominated tokenised deposit transfers between the UAE and international markets, including Hong Kong and Singapore. These transactions were initiated via WhaleRTP – Ant International’s proprietary, blockchain-based real-time treasury managem
RoslinCT Awarded £7.25 million Scottish Enterprise R&D Grant to Advance Digital Cell Therapy Manufacturing6.10.2026 08:00:00 CEST | Press release
RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it has been awarded a Research & Development grant from Scottish Enterprise to accelerate the digital transformation of its manufacturing operations in Scotland. The funding, supported by a Scottish Enterprise R&D grant of up to £7.25 million, forms part of RoslinCT's ambitious digital expansion plan, a multi-year initiative designed to enhance the company's integrated digital and AI capabilities and further strengthen Scotland's position as a global hub for advanced cell and gene therapy manufacturing. The programme will enable the development of a digitally integrated manufacturing environment, improving operational efficiency, data connectivity and manufacturing excellence across RoslinCT's operations. By creating a more connected and data-driven manufacturing environment, RoslinCT will be better positioned to support clients throughout the product lifecycle, helping b
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation6.10.2026 07:00:00 CEST | Press release
Galderma celebrates the 30th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market1 With three decades of innovation across technology, packaging, and treatment areas, Restylane continues to meet growing aesthetic needs, including emerging areas such as medication-driven weight loss, skin quality and menopause1-11 This year’s milestones include the approvals of Restylane Shaype™ in the European Union (EU) for enhancement of the chin region, the new state-of-the-art Restylane syringe in the EU, United States (U.S.), and Canada, and Restylane Volyme™* in the U.S. for temple hollowing, with a dual-layer patent-pending technique leveraging both needle and cannula12-18 With more than 80 clinical trials, 180 publications, around 407,000 patients evaluated for safety, and 77 million treatments administered worldwide, Restylane remains a pioneer in science-backed aesthetic innovation and continues to shape the fu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom